Dechra US Agreement

Dechra Pharmaceuticals PLC
15 May 2007


Issued on behalf of Dechra Pharmaceuticals PLC
Date: Tuesday, 15 May 2007                                      Embargoed:7.00am



                           Dechra Pharmaceuticals PLC
                           ('Dechra' or 'the Group')
             Dechra Strengthens its US Veterinary Product Portfolio

Dechra today announces that it has secured a long-term trademark license and
supply agreement with Pharmaderm Animal Health ('Pharmaderm'), part of the US
commercial division of ALTANA Inc.

The agreement provides the Group with exclusive marketing and distribution
rights for a range of veterinary licensed ophthalmic, otic and dermatological
products and the opportunity to develop new veterinary licenses for both North
America and Europe.

Under the agreement, Dechra will pay US$5million in cash for the licenses. The
products, which are currently sold to veterinary practices in the USA, achieved
sales of US$7.7 million in the year ended 31 December 2006.

This range of specialist products, which will continue to be manufactured by
ALTANA's US commercial division on behalf of Dechra, will be marketed and
distributed under the Dechra Veterinary Products brand livery.  The agreement
will provide the opportunity for the Group to increase sales and to strengthen
its profile and brand awareness within the American veterinary market ahead of
the launch of its own developed veterinary products, Vetoryl(R), Felimazole(R)
and Equidone(R) which are currently undergoing FDA review.

Ian Page, Chief Executive, Dechra Pharmaceuticals PLC said:

'We are delighted to have significantly strengthened our range of specialist
veterinary medicines for the US market. We are confident that our technical and
marketing expertise can increase market penetration of this specialist product
range and, when combined with our own-developed products, will enable us to
establish a much stronger foothold and brand awareness within the US-veterinary
companion animal market, the largest in the world.'


Enquiries:
Ian Page, Chief Executive                    Fiona Tooley, Director
Simon Evans, Group Finance Director          Citigate Dewe Rogerson
Dechra Pharmaceuticals PLC                   Telephone:     [phone]
Telephone:      [phone]          Mobile:        [phone]
Mobile:         [phone] (IP)
Mobile:         [phone] (SE)
www.dechra.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange